COMMENTARY: The longevity boom is solving the wrong problem

At 51, I am often told I don’t look my age. At conferences, I have been mistaken for an intern. A few years ago, my son accompanied me to a school reunion, scanned my classmates, men the same age as me, and said, “Papa, they look like your grand uncles.”

It was funny. It was also revealing.

Because it feeds into a powerful illusion that aging is visible, controllable, even optimizable. That with enough discipline, we can engineer youth.

That illusion is now a global industry. By some estimates, the longevity and anti-aging market is headed toward a multitrillion-dollar size over the next decade. In India, my home country, this is playing out alongside a different reality: 100 million people living with diabetes and a rapidly rising burden of cardiovascular disease.

On paper, I fit the “fit” stereotype: a BMI of 21.5, vegan, reasonably fit, energetic through the day. That story is incomplete.

A few years ago, I lost my mother. Grief does not remain contained; it seeps into sleep, appetite and the quiet moments you cannot distract yourself from. Alongside that, I’ve spent decades in a high-pressure global career — rewarding, certainly, but also stressful and, at times, bruising.

My medical reports are candid: rising cholesterol, a significant degree of fatty liver. Stress leaves its mark. The body keeps score, even when appearances suggest otherwise.

If I seem younger, it is not because life has been easy. It is because something else has mattered.

Family, deeply supportive and unconditionally present. Friends across geographies. And curiosity: reading, writing, conversations that energize. These are not lifestyle hacks. They may matter more than most of what passes for “longevity science” today.

After more than two decades in the pharmaceutical industry across health systems in more than 100 countries, I find the current longevity boom deeply unconvincing. It is an industry built on sleek packaging, confident claims and limited evidence. Supplements promising cellular rejuvenation. Ice baths at 5 a.m. marketed as discipline. Biological age “reversal” sold at a premium.

The science, for the most part, does not support the claims. Not yet.

This matters even more in India and in emerging markets worldwide. We are simultaneously facing a surge in lifestyle diseases and a booming wellness economy. The risk is that longevity becomes an elite obsession, while the basics of public health remain unevenly addressed.

Consider Japan, often held up as the global model. It has one of the highest life expectancies in the world. Yet, it also faces a severe loneliness crisis. A crisis significant enough to warrant a “Minister for Loneliness” in the Japanese government. Longer lives, but not necessarily better ones.

This is where the longevity narrative goes wrong. It obsesses over biology — over things such as telomeres, mitochondria, senescent cells.

Important, yes, but incomplete.

Because the most powerful drivers of aging are not just biological. They are psychological and social.

Chronic stress accelerates aging through measurable pathways. Social isolation, according to large meta-analyses, carries a mortality risk comparable to smoking up to 15 cigarettes a day. Loneliness is not metaphorical. It is biological.

The inverse is equally true. Strong relationships, emotional resilience and a sense of purpose are associated with lower inflammation, better health outcomes and longer lives.

Yet, the most reliable levers of longevity remain stubbornly unmarketable: regular movement, adequate sleep, balanced nutrition, low chronic stress, meaningful relationships and purpose.

In other words, the basics. Executed consistently, over decades.

Even the most promising advances, such as epigenetic clocks, senolytics and next-generation metabolic drugs, remain in their early stages. The gap between laboratory insight and real-world effect is wide. Claims of “reversing aging” today are, at best, speculative.

Which leads to an inconvenient conclusion: Longevity is not a product category. It is the cumulative outcome of how we live: physically, emotionally and socially. Not just discipline, but introspection. Not just optimization, but connection.

The real test of a longevity revolution is not how long a few can live, but how well many can age.

Everything else is branding.

Deepak Sapra is the CEO of pharmaceutical services and active pharmaceutical ingredients at Dr. Reddy’s Laboratories. He wrote this for InsideSources.com.